After discussions with the U.S. Food and Drug Administration, Paris-based Ipsen withdrew the company’s New Drug Application (NDA) for palovarotene.

Ipsen decided to temporarily pause dosing in the company’s palovarotene extension studies for patients with fibrodysplasia ossificans progressiva following a recommendation from an Independent Data Monitoring Committee.

Scientists at U.S. biotechnology company Regeneron Pharmaceuticals researching a rare genetic disease that traps sufferers in a second skeleton have discovered a treatment that shuts down excessive bone growth in […]